Methadone Deaths: Risk Factors in Pain and Addicted Populations Authors
First Online: 20 January 2010 Received: 03 November 2008 Revised: 06 May 2009 Accepted: 10 December 2009 DOI:
Cite this article as: Modesto-Lowe, V., Brooks, D. & Petry, N. J GEN INTERN MED (2010) 25: 305. doi:10.1007/s11606-009-1225-0
Methadone is highly effective in treating opioid dependence, and it is also used as an analgesic for second-line management of chronic pain. However, recent increases in methadone-related deaths have instigated controversy about the use of this medication. In this paper, we evaluate risk factors for methadone mortality in opioid dependent and pain populations and present guidelines for initiating methadone treatment in these two populations to minimize the risk of death. Early research with methadone-maintained patients revealed that methadone fatalities occur primarily due to respiratory arrest during methadone induction and in the context of polysubstance use. Recent reports of methadone deaths emphasize chronic pain populations, methadone-related QTc prolongation, and the possibility of inducing Torsade de pointes (TdP), a potentially fatal ventricular arrhythmia. Retrospective analyses of these deaths show that patients who develop TdP often present with multiple risk factors, including high methadone doses, use of other medications that cause QTc prolongation, and electrolyte abnormalities. To minimize fatalities, guidelines are presented for initiating methadone in opioid treatment and pain populations that consider the drug’s pharmacology along with behavioral, medical and psychiatric risk factors.
Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L.
Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005;100:981–9.
Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S.
Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103:462–8.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;CD002209.
Shaiova L, Berger A, Blinderman CD, et al.
Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008;6:165–76.
Trescot AM, Helm S, Hansen H, et al.
Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians Guidelines. Pain Physician. 2008;11(2suppl):S5–62.
Graham NA, Merlo LJ, Goldberger BA, Gold MS.
Methadone and heroin-related deaths in Florida. Am J Drug Alcohol Abuse. 2008;34:347–53.
CSAT: Methadone-Associated Mortality: Report of a National Assessment, 2003.SAMHSA Publication. N0.04-3904. Available at:
. Accessed September 16, 2008.
Srivasatava A, Kahan M.
Methadone induction doses: are our current practices safe? J Addict Dis. 2006;25:5–13.
Modesto-Lowe V, Johnson K, Petry NM.
Pain management in patients with substance abuse: treatment challenges for pain and addiction specialists. Am J Addict. 2007;16:424–5.
Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity. Drug Alcohol Rev. 1998;17:9–17.
Caphehorn JR, Drummer OH.
Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002;26:358–62.
Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage. 2008;36:545–52.
FDA Public Health Advisory. Methadone use for pain control may result in death and life-threatening changes in breathing and heart beat. Available at:
. Accessed September 19, 2008.
Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K.
A Community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med. 2008;121:66–71.
Corkery JM, Schifano F, Ghodse AH, Oyefeso A.
The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004;19:565–76.
Ehret GB, Desmeules JA, Broers B.
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Exper Opin Drug Saf. 2007;6:289–303.
Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S.
Methadone-induced Torsade de pointes tachycardias. Swiss Med Wkly. 2005;135:282–5.
Williamson PA, Foreman KJ, White JM, Anderson G.
Methadone-related overdose deaths in South Australia, 1984–1994. How safe is methadone prescribing? Med J Aust. 1997;166:302–5.
Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990–1995. 2000;95:77–84.
Zador DA, Sunjic SD.
Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev. 2002;21:131–6.
Hummeniuk R, Ali R, McGregor C, Darke S.
Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction. 2003;98:413–8.
Karch SB, Stephens BG.
Toxicology and pathology of deaths related to methadone: retrospective review. West J Med. 2000;172:11–4.
Fischer B, Cruz MF, Rehm J.
Illicit opioid use and its key characteristics: A select overview and evidence from a Canadian multisite cohort of illicit opioid users. Can J Psychiatry. 2006;51:624–34.
Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM.
What clinicians should know about QT Interval. JAMA. 2003;289:2120–7.
Methadone-induced long QT syndrome vs methadone-induced Torsades de Pointes. Arch Int Med. 2006;166:2288.
Lipski J. Stimmel B, Donosco E.
The effect of heroin and multiple drug abuse on the electrocardiogram. Am Heart J. 1973;86:663-8.
Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS.
Torsade de pointes associated with very-high dose methadone. Ann Intern Med. 2002;137:501–4.
Pearson EC, Woosley RL.
QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747–53.
Stringer J, Welsh C, Tommasello A.
Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm. 2009;66:825–33.
Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH.
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590–7.
Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC.
QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387–95.
The College of Physicians & Surgeons of Ontario. Methadone for Pain Guidelines 2004. Available at:
. Accessed September 22, 2008.
Walker JM, Farney RJ.
Are opioids associated with sleep apnea? A review of the evidence. Curr Pain Headache Rep. 2009;2:120–6.
Characterization of methadone overdose: clinical considerations and the scientific evidence. Ther Drug Monit. 2002;24:457–70.
Modesto-Lowe V, Brooks D, Freedman K, Hargus E.
Addiction and chronic pain: diagnostic and treatment dilemmas. Conn Med. 2007;71:139–44.
Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2008;CD004147.
Divided doses for methadone maintenance. Am J Psychiatry. 2008;165:1358.
Methadone: an effective, safe drug of first choice for pain management in frail older adults. Pain Med. 2009;10:319–26.
Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O.
Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008;52:879–89.
Andrews CM, Krantz MJ, Wedam EF, Marcuson MJ, Capacchione JF, Haigney MC.
Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J. 2009;16:210–7.
Pergolizzi J, Boger RH, Budd K, et al.
Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313.
Lamb L, Pereira JX, Shir Y.
Nurse case management program of chronic pain patients treated with methadone. Pain Manag Nurs. 2007;8:130–8.
CrossRef PubMed Copyright information
© Society of General Internal Medicine 2010